Understanding T cell responses and T cell signaling in human airway organoids with SARS-CoV-2 infection
Project Number3P01AI091580-10S1
Contact PI/Project LeaderWEISS, ARTHUR
Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
PROJECT ABSTRACT
The SARS coronavirus-2 (SARS-CoV-2) has rapidly emerged over the past four months leading to a critical
pandemic of coronavirus disease (COVID-19) with over 1.4M cases worldwide
(https://coronavirus.jhu.edu/map.html) and roughly 100,000 projected fatalities in the US alone by August
2020 (See https://covid19.healthdata.org/projections). SARS-CoV-2 causes a lethal ARDS. Despite our
improved mechanistic understanding of ARDS, intervention clinically is challenging. NOT-AI-20-31 indicated
several needs, such as development of reagents and assays for virus characterization, understand critical
aspects of viral infection, replication, pathogenesis, and transmission, identification and evaluation of the
cellular and humoral immune responses to SARS-CoV-2, which we address in this proposal.
Indeed, there is an urgent need to understand the immunopathology of COVID-19 and study the
interactions of the lung epithelium and tissue, the immune system and the virus to understand the biology of
this multipartite interaction. We need to better understand the immunopathology of COVID-19 to explore
novel therapeutic approaches that have the potential to work in COVID-19 patients.
Our proposal addresses this need from the perspective of the lung epithelium response to SARS-
CoV-2 infection and from a T cell perspective in COVID-19. Simultaneously, or efforts will also provide a
sharable research platform of lung airway organoids/SARS-CoV-2/immune cells that will expedite testing of
experimental therapeutics. Results from my supplement program will be shared with Drs. Gordon, Looney,
and Krummel in our ‘RapidPath’ program (see supporting letter) to promote rapid discovery and progress
and will be compared to insights from COVID-19 patient immune systems, being simultaneously profiled in
the UCSF IMPACC project. In this this Administrative Supplement we will capitalize on my lab’s established
expertise in T cell signaling, T cell activation, antigen recognition, inflammation, and autoimmune diseases.
Those are broad topics of the parent P01 (2P01AI091580, Weiss). Uniquely, we will combine our T cell
expertise with our expertise in the generation and studies of epithelial cell organoids. We already have an
“Airway Organoid Biobank” that we will expand as a resource for the community. We will characterize the
epithelial response to six different SARS-CoV-2 strains compared to H1N1pdm virus, using airway
organoid-, single cell RNAseq-, and CyTOF- technology (Aim 1). In order to better understand SARS-CoV-2
and adaptive immunity, we will obtain mechanistic insights into T cell activation and T cell signaling in the
context of SARS-CoV-2- and H1N1pdm- infection of seven, diverse Airway Organoids and two NSCLC
organoids (Aim 2). High-resolution imaging and CyTOF analysis of these “virus-T cell-organoids” will
provide much needed immunological insights into SARS-CoV-2 and its T cell biology as indicated in NOT-
AI-20-31 and will synergize with other projects in ‘RapidPath’ and in UCSF IMPACC programs.
Public Health Relevance Statement
PUBLIC HEALTH RELEVANCE: In this program project renewal, our overall goal is to capitalize on our current progress and bring together approaches from structural biology, proteomics, immunology, and computational biology to understand TCR signaling. In project #1, we will study the distinct features of the T cell-expressed tyrosine kinases that make these most suitable for antigen receptor (TCR) signaling in T cells. In project #2, we hope to understand how TCR signaling regulates Ras, a critical regulator of cell activation, to establish basal homeostasis and allow for efficient activation of T cell responses.
Project-001: Project 1
Project Leader (PL): Weiss, Arthur
DESCRIPTION (provided by applicant): This application is a renewal of an ongoing project in which four investigators with different but complementary expertise have worked together to understand how the T cell antigen receptor (TCR) regulates the proximal tyrosine kinases (SFKs, Syk kinases and Tec kinases) that control critical downstream tyrosine phosphorylation. We have made considerable progress in understanding the structural basis for the specificity differences that are encoded in the kinase domains and the autoregulatory constraints that control the activities of these kinases, but a full understanding will require new approaches. We propose to capitalize on our current progress and bring together approaches from structural biology, physical sciences, proteomics, immunology, and computational biology to perform studies that are aimed at understanding the distinct features of the T cell-expressed SFKs, Syk and Tec kinases that make the individual kinases more suitable for antigen receptor signaling in T cells than in B cells. We hypothesize that the characteristics of Lck and Fyn, ZAP-70 and Itk and their signaling regulators have been optimized in T cells to establish signaling circuitry that serves to maintain a basal signaling state that is resistant to perturbations by non- agonist peptides and also establishes a sensitive threshold for optimal recognition and response to agonist pMHC. We will explore this hypothesis in experiments designed to: 1) understand the unique features of the proximal kinases that are advantageous in TCR signaling; 2) define the regulatory mechanisms that constrain the activity of the proximal tyrosine kinases; 3) determine how TCRs maintain basal homeostasis and distinguish biological noise from antigenic stimuli; and, 4) define the key intracellular events needed to initiate downstream signal propagation by the TCR.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
18-May-2020
Project End Date
30-June-2021
Budget Start Date
01-July-2020
Budget End Date
30-June-2021
Project Funding Information for 2020
Total Funding
$405,310
Direct Costs
$250,966
Indirect Costs
$154,344
Year
Funding IC
FY Total Cost by IC
2020
National Institute of Allergy and Infectious Diseases
$405,310
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3P01AI091580-10S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3P01AI091580-10S1
Patents
No Patents information available for 3P01AI091580-10S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3P01AI091580-10S1
Clinical Studies
No Clinical Studies information available for 3P01AI091580-10S1
News and More
Related News Releases
No news release information available for 3P01AI091580-10S1
History
No Historical information available for 3P01AI091580-10S1
Similar Projects
No Similar Projects information available for 3P01AI091580-10S1